Co­herus re­struc­tures, ax­es 51 staffers in wake of an FDA re­jec­tion of its knock­off of Am­gen’s Neu­las­ta

Just two weeks af­ter the FDA spurned Co­herus’ ap­pli­ca­tion to sell a knock­off of Am­gen’s Neu­las­ta, the biosim­i­lar mak­er has come back with a plan to ax 51 staffers — about 30% of its em­ploy­ees — as it hun­kers down to weath­er the de­rail­ment.

The news ear­li­er this month marked a re­prieve for Am­gen, which counts this drug as one of its main­stays. Am­gen has been both lucky and good at hold­ing off biosim­i­lar com­pe­ti­tion to its ag­ing flag­ship drugs, with Pfiz­er get­ting its sec­ond de­lay af­ter the FDA found prob­lems with its man­u­fac­tur­ing site in Kansas. And that pitch had been blessed by in­side and out­side ex­perts at the agency.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.